P4‐389: ELENBECESTAT, E2609, A BACE INHIBITOR: RESULTS FROM A PHASE‐2 STUDY IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT AND MILD‐TO‐MODERATE DEMENTIA DUE TO ALZHEIMER'S DISEASE
The DOI matches its Crossref record.
Abstract
This Phase-2, 18-month, placebo-controlled study investigated the safety of elenbecestat in MCI-to-moderate AD subjects and explored its effects on biomarkers and clinical endpoints. Subjects were diagnosed as AD (NIA-AA 2011 criteria) and confirmed as amyloid-PET+ before being randomized to placebo, elenbecestat 5, 15, or 50-mg/day. While ongoing, the study was amended; subjects with ≥3 months of treatment remaining were reassigned from elenbecestat 5- and 15-mg/day to 50-mg/day. Subjects who received ≥3 months of elenbecestat 50-mg/day were analyzed as the 50-mg/day Total group. Safety measures included incidences of TEAEs and clinical laboratory assessments. Clinical effectiveness (CDR-SB) and effect on amyloid load (amyloid-PET) were explored by comparing changes from baseline (CFB) to 18 months between 50mg/day Total vs placebo. Longitudinal amyloid-PET was obtained from 28 subjects with florbetaben and 7 subjects with florbetapir. Analyses of mean CFB in CDR-SB and mean %-CFB in cortical composite PET SUVR values (ratio of average of tracer-specific cortical regions to whole cerebellum) were based on ANCOVA with baseline values as covariates. This study randomized 70 subjects: 43 (61%) completed the study; 27 (39%) discontinued early. No deaths occurred. Incidences of TEAEs and TEAEs leading to treatment discontinuation were similar for 50-mg/day Total and placebo. No dose-dependent response relationship was observed. No subject discontinued due to liver toxicity. Although sample sizes for PET SUVR analyses were small, statistically significant mean treatment differences of -5.8% (p=0.013) and -13.6% (p=0.014) were observed between 50mg/day Total vs placebo in the florbetaben (placebo=7; 50-mg/day Total=21) and florbetapir (placebo=4; 50-mg/day Total=3) subgroups, respectively. The 50mg/day Total group (n=29) demonstrated a mean treatment difference of -0.5 (>30% less decline) in CDR-SB vs placebo (n=12) which was not statistically significant (p=0.55) in this small study. Subgroup analysis of subjects with baseline florbetapen PET SUVR values within 1.4-1.9, showed that those in the 50-mg/day Total group demonstrated 72% less decline in CDR-SB vs placebo. Elenbecestat was generally well tolerated; no unexpected safety concerns emerged. Although sample sizes were small, statistically significant decreases in PETSUVR were seen. Clinical assessments suggest elenbecestat may have attenuating effects on cognitive decline in MCI-to-moderate AD subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Pivotal Role of NF-kB in the Pathogenesis and Therapeutics of Alzheimer’s Disease
Sun, E., Motolani, A., Campos, L., & Lu, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168972 · Cited by 361
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
Investigational BACE inhibitors for the treatment of Alzheimer’s disease
Imbimbo, B. P., & Watling, M. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1683160 · Cited by 132
Selective Secretase Targeting for Alzheimer’s Disease Therapy
Miranda, A., Montiel, E., Ulrich, H., & Paz, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201027 · Cited by 66
Is It the Twilight of BACE1 Inhibitors?
Hrabinova, M., Pejchal, J., Kucera, T., Jun, D., Schmidt, M., & Soukup, O. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200503023323 · Cited by 28
Metadata
- Authors
- Lynch, S. Y., Kaplow, J., Zhao, J., Dhadda, S., Luthman, J., & Albala, B.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2018-07
- Volume
- 14
- Issue
- 7S_Part_31
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2896271121
- Cited by
- 35
- References
- 0
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: P4‐389: ELENBECESTAT, E2609, A BACE INHIBITOR: RESULTS FROM A PHASE‐2 STUDY IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT AND MILD‐TO‐MODERATE DEMENTIA DUE TO ALZHEIMER'S DISEASE. https://app.cochat.ai/papers/10.1016/j.jalz.2018.07.213
- The paper
- Lynch, S. Y., Kaplow, J., Zhao, J., Dhadda, S., Luthman, J., & Albala, B. (2018). P4‐389: ELENBECESTAT, E2609, A BACE INHIBITOR: RESULTS FROM A PHASE‐2 STUDY IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT AND MILD‐TO‐MODERATE DEMENTIA DUE TO ALZHEIMER'S DISEASE. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2018.07.213
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.